- Home
- REFI vs BMEA Comparison
REFI vs BMEA Comparison
Compare REFI & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- BMEA
- Stock Information
- Founded
- REFI 2021
- BMEA 2017
- Country
- REFI United States
- BMEA United States
- Employees
- REFI N/A
- BMEA N/A
- Industry
- REFI Real Estate Investment Trusts
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- REFI Real Estate
- BMEA Health Care
- Exchange
- REFI Nasdaq
- BMEA Nasdaq
- Market Cap
- REFI 306.1M
- BMEA 275.6M
- IPO Year
- REFI 2021
- BMEA 2021
- Fundamental
- Price
- REFI $15.97
- BMEA $6.38
- Analyst Decision
- REFI Buy
- BMEA Buy
- Analyst Count
- REFI 2
- BMEA 13
- Target Price
- REFI $20.00
- BMEA $37.25
- AVG Volume (30 Days)
- REFI 71.8K
- BMEA 814.9K
- Earning Date
- REFI 11-07-2024
- BMEA 10-29-2024
- Dividend Yield
- REFI 11.78%
- BMEA N/A
- EPS Growth
- REFI N/A
- BMEA N/A
- EPS
- REFI 2.00
- BMEA N/A
- Revenue
- REFI $56,860,278.00
- BMEA N/A
- Revenue This Year
- REFI N/A
- BMEA N/A
- Revenue Next Year
- REFI $4.27
- BMEA N/A
- P/E Ratio
- REFI $7.98
- BMEA N/A
- Revenue Growth
- REFI 6.49
- BMEA N/A
- 52 Week Low
- REFI $14.82
- BMEA $3.61
- 52 Week High
- REFI $17.65
- BMEA $22.74
- Technical
- Relative Strength Index (RSI)
- REFI 64.15
- BMEA 24.23
- Support Level
- REFI $15.47
- BMEA $6.04
- Resistance Level
- REFI $15.92
- BMEA $9.34
- Average True Range (ATR)
- REFI 0.18
- BMEA 0.54
- MACD
- REFI 0.06
- BMEA -0.26
- Stochastic Oscillator
- REFI 96.77
- BMEA 10.30
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.